Reversair CT 10 mg (Chewable Tablet)

Title

• Reversair CT 10 mg Chewable Tablet

Categories

• Medicine
• Health & Wellness

Description

• Reversair CT 10 mg Chewable Tablet is a medication indicated for the prophylaxis and chronic treatment of asthma, acute prevention of Exercise-Induced Bronchoconstriction (EIB), and relief of symptoms of Allergic Rhinitis (AR) - Seasonal & Perennial Allergic Rhinitis.

Indication

• Prophylaxis and chronic treatment of asthma
• Acute prevention of Exercise-Induced Bronchoconstriction (EIB)
• Relief of symptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis

Pharmacology

• Selective and orally active leukotriene receptor antagonist
• Inhibits the cysteinyl leukotriene receptor (CysLT1)
• Correlated with the pathophysiology of asthma & allergic rhinitis
• Contributes to signs and symptoms of asthma

DosageAdministration

• Adults and adolescents: Montelukast 10 mg tablet once daily
• Pediatric patients: Montelukast 5 mg tablet once daily (6-14 years), 4 mg tablet once daily (2-5 years), 4 mg oral granules once daily (6 months-5 years)

Interaction

• Administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma
• No clinically important effects on the pharmacokinetics of theophylline, prednisone, terfenadine, digoxin, and warfarin
• Used concomitantly with a wide range of commonly prescribed drugs without evidence of clinical adverse interactions

Contraindications

• Contraindicated in patients hypersensitive to any component of the product

SideEffects

• Common: Diarrhoea, fever, headache, nausea, vomiting
• Uncommon: Anxiety, dizziness, dry mouth, sleep disorders
• Rare: Angioedema, hallucination, memory loss, palpitations

PregnancyLactation

• Montelukast crosses the placenta in rats and rabbits
• Caution advised during pregnancy and lactation

PrecautionsWarnings

• Not indicated for use in the reversal of bronchospasm in acute asthma attacks
• Should not be abruptly substituted for inhaled or oral corticosteroids
• Not to be used as monotherapy for the treatment of exercise-induced bronchospasm

OverdoseEffects

• No adverse experiences in the majority of overdosage reports
• Usual supportive measures recommended in the event of overdose

TherapeuticClass

• Leukotriene receptor antagonists

StorageConditions

• Store below 30°C, protect from light & moisture, keep out of reach of children

ChemicalStructure

• Molecular Formula: C35H36ClNO3S
• Chemical Structure Image: Link to image provided

CommonlyAskedQuestions

• What is Reversair CT 10 mg Chew. Tablet?
• What is it used for?
• How soon can the effect be observed?
• How long does the effect last?
• Should it be taken empty stomach?
• Pregnancy warnings
• General Instructions

Dimensions

• Not Applicable

ColorOptions

• Not Applicable

Functions

• Prophylaxis and chronic treatment of asthma
• Prevention of Exercise-Induced Bronchoconstriction
• Relief of Allergic Rhinitis symptoms

Materials

• Not Applicable

TechnicalSpecifications

• Not Applicable

DesignElements

• Not Applicable

UsabilityFeatures

• Not a fast-acting rescue medicine for asthma attacks
• Caution advised for patients with known aspirin sensitivity

AgeGroup

• Adults
• Adolescents
• Pediatric patients

SafetyFeatures

• No clinically important effects on the pharmacokinetics of certain drugs

PackagingInformation

• Store in a cool, dry place
• Protect from light and moisture

LegalDisclaimer

• Not Applicable

AdditionalAttributes

• No dosage adjustment required in hepatic insufficiency or renal insufficiency
• Similar pharmacokinetic profile in elderly and younger adults
• Caution advised when co-administered with potent cytochrome P450 enzyme inducers

Related Brands

• Aeron FT 4 mg (Dispersible Tablet) - healthcare-pharmaceuticals-ltd
• Aeron FT 5 mg (Dispersible Tablet) - healthcare-pharmaceuticals-ltd
• Aeron 10 mg (Tablet) - healthcare-pharmaceuticals-ltd
• Montinex 4 mg (Chewable Tablet) - beacon-pharmaceuticals-plc
• Montinex 5 mg (Chewable Tablet) - beacon-pharmaceuticals-plc